Models of RNA virus evolution and their roles in vaccine design

Immunome Research

Volumn 6, Issue SUPPL. 2, 2010, Pages

  Ojosnegros, Samuel ^a,b   Beerenwinkel, Niko ^a  

^a ETH ZURICH   (Switzerland)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PEPTIDE BASED VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

DRUG DESIGN; HUMAN; IMMUNIZATION; MATHEMATICAL MODEL; MOLECULAR EVOLUTION; NONHUMAN; PHYLOGENY; REVIEW; RNA VIRUS; VACCINATION; VIRULENCE; VIRUS REPLICATION; VIRUS STRAIN;

RNA VIRUSES;

EID: 78149300148     PISSN: None     EISSN: 17457580     Source Type: Journal    
DOI: 10.1186/1745-7580-6-S2-S5     Document Type: Review

References (175)

1. Principles of Virology. Molecular Biology, Pathogenesis, and Control of Animal Viruses. SJ Flint LW Enquist VR Racaniello AM Skalka, Washington, D.C.: ASM Press second 2004
2. Virus Evolution. E Domingo, Fields Virology Philadelphia: Lappincott Williams & Wilkins, Knipe DM, Howley PM, 5 2007 12 389 421
3. The causes and consequences of HIV evolution. A Rambaut D Posada KA Crandall EC Holmes, Nat Rev Genet 2004 5 1 52 61 10.1038/nrg1246 14708016
4. The population genetics and evolutionary epidemiology of RNA viruses. A Moya EC Holmes F Gonzlez-Candelas, Nat Rev Microbiol 2004 2 4 279 288 10.1038/nrmicro863 15031727
5. Measurably evolving populations. AJ Drummond OG Pybus A Rambaut R Forsberg AG Rodrigo, TRENDS Ecol Evol 2003 18 9 481 488 10.1016/S0169-5347(03) 00216-7 (Pubitemid 37007509)
6. Mutation rates among RNA viruses. JW Drake JJ Holland, Proc Natl Acad Sci USA 1999 96 13910 13913 10.1073/pnas.96.24.13910 10570172
7. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. M Vignuzzi JK Stone JJ Arnold CE Cameron R Andino, Nature 2006 439 7074 344 348 10.1038/nature04388 16327776
8. Increased fidelity reduces poliovirus fitness under selective pressure in mice. JK Pfeiffer K Kirkegaard, PLoS Pathog 2005 1 11 10.1371/journal.ppat. 0010011 16220146
9. Virus evolution: the importance of being erroneous. S Bonhoeffer P Sniegowski, Nature 2002 420 6914 367 369 10.1038/420367a 12459766
10. Pre-existence and emergence of drug resistance in HIV-1 infection. S Bonhoeffer MA Nowak, Proc Biol Sci 1997 264 1382 631 637 10.1098/rspb.1997.0089 9178534
11. Influence of the mutant spectrum in viral evolution: focused selection of antigenic variants in a reconstructed viral quasispecies. V Martin E Domingo, Mol Biol Evol 2008 25 1544 1554 10.1093/molbev/msn099 18436553
12. Molecular quasi-species. M Eigen J McCaskill P Schuster, J Phys Chem 1988 92 24 6881 6891 10.1021/j100335a010
13. RNA virus mutations and fitness for survival. E Domingo JJ Holland, Annu Rev Microbiol 1997 51 151 178 10.1146/annurev.micro.51.1.151 9343347
14. RNA virus populations as quasispecies. JJ Holland JCDL Torre DA Steinhauer, Curr Top Microbiol Immunol 1992 176 1 20 1600747
15. Viral evolution under the pressure of an adaptive immune system: Optimal mutation rates for viral escape. C Kamp CO Wilke C Adami S Bornholdt, Complexity 2003 8 2 28 33 10.1002/cplx.10067
16. Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. S Ojosnegros R Agudo M Sierra C Briones S Sierra C Gonzalez-Lopez E Domingo J Cristina, BMC Evol Biol 2008 8 207 10.1186/1471-2148-8-207 18637173
17. Viral population estimation using pyrosequencing. N Eriksson L Pachter Y Mitsuya S-Y Rhee C Wang B Gharizadeh M Ronaghi RW Shafer N Beerenwinkel, PLoS Comput Biol 2008 4 4 1000074 10.1371/journal.pcbi.1000074 18437230
18. Evolutionary analysis of the dynamics of viral infectious disease. OG Pybus A Rambaut, Nat Rev Genet 2009 10 8 540 550 10.1038/nrg2583 19564871
19. Timing the ancestor of the HIV-1 pandemic strains. B Korber M Muldoon J Theiler F Gao R Gupta A Lapedes BH Hahn S Wolinsky T Bhattacharya, Science 2000 288 5472 1789 1796 10.1126/science.288.5472.1789 10846155
20. Tracing the origin and history of the HIV-2 epidemic. P Lemey OG Pybus B Wang NK Saksena M Salemi A-M Vandamme, Proc Natl Acad Sci U S A 2003 100 11 6588 6592 10.1073/pnas.0936469100 12743376
21. The genomic and epidemiological dynamics of human influenza A virus. A Rambaut OG Pybus MI Nelson C Viboud JK Taubenberger EC Holmes, Nature 2008 453 7195 615 619 10.1038/nature06945 18418375
22. Predicting the evolution of human influenza A. RM Bush CA Bender K Subbarao NJ Cox WM Fitch, Science 1999 286 5446 1921 1925 10.1126/science.286. 5446.1921 10583948
23. Adaptation and the comparative method. Martins, Trends Ecol Evol 2000 15 7 296 299 10.1016/S0169-5347(00)01880-2 10856957
24. Brock. Madigan Martinko Parker, Biology of Microorganisms Prentice-Hall, Inc. 2001
25. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. E Domingo L Menendez-Arias ME Quinones-Mateu A Holguin M Gutierrez-Rivas MA Martinez J Quer IS Novella JJ Holland, Prog Drug Res 1997 48 99 128 9204684
26. Ribavirin: a broad spectrum antiviral agent. RA Smith W Kirkpatrick, New York: Academic Press, Inc. 1980
27. Lassa fever. Effective therapy with ribavirin. JB McCormick IJ King PA Webb CL Scribner RB Craven KM Johnson LH Elliott R Belmont-Williams, N Engl J Med 1986 314 1 20 26 10.1056/NEJM198601023140104 3940312
28. Ribavirin's antiviral mechanism of action: lethal mutagenesis? S Crotty C Cameron R Andino, J Mol Med 2002 80 2 86 95 10.1007/s00109-001-0308-0 11907645
29. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. S Crotty D Maag JJ Arnold W Zhong JYN Lau Z Hong R Andino CE Cameron, Nature Medicine 2000 6 1375 1379 10.1038/82191 11100123
30. Benefits and risks of interferon therapy for hepatitis B. R Perrillo, Hepatology 2009 49 5 Suppl 103 111 10.1002/hep.22956 19399806
31. Hepatitis C therapy-the future looks bright. SA Qureshi H Qureshi A Hameed, Eur J Clin Microbiol Infect Dis 2009 19727870
32. Antiviral drugs in current clinical use. E De Clercq, J Clin Virol 2004 30 2 115 133 10.1016/j.jcv.2004.02.009 15125867
33. Global transmission of oseltamivir-resistant influenza. A Moscona, N Engl J Med 2009 360 10 953 956 10.1056/NEJMp0900648 19258250
34. The vaccine book. BR Bloom PH Lambert, Amsterdan: Academic Press 2003
35. Immunization against viral diseases. BS Graham JE Crowe Jr., Fields Virology Philadelphia: Lappincott Williams & Wilkins, Knipe DM, Howley PM, 5 2007 12 z 389 421
36. Properties and behavior of orally administered attenuated poliovirus vaccine. AB Sabin, J Am Med Assoc 1957 164 11 1216 1223 13438685
37. The Use of Yellow Fever Virus Modified by in Vitro Cultivation for Human Immunization. M Theiler HH Smith, J Exp Med 1937 65 6 787 800 10.1084/jem.65.6.787 19870634
38. Inactivated poliovirus vaccine: past and present experience. AD Murdin L Barreto S Plotkin, Vaccine 1996 14 8 735 746 10.1016/0264-410X(95)00211-I 8817819
39. Immunobiology. A Janeway P Travers M Walport M Shlomchik, The immune system in health and disease New York: Garland Publishing 5 2001
40. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. HG Bahnemann, Vaccine 1990 8 4 299 303 10.1016/0264-410X(90)90083-X 2204242
41. Modern Inactivated Foot-and-Mouth Disease (FMD) Vaccines: Historical Background and Key Elements in Production and Use. SJ Barteling, Foot-and-mouth Disease: Current Perspectives England: Horizon Bioscience, Sobrino F, Domingo E. Wymondham, 2004 305 334
42. Universal mass vaccination against hepatitis A. FE Andre, Curr Top Microbiol Immunol 2006 304 95 114 full-text 16989266
43. Influenza vaccine supply: building long-term sustainability. N Hehme T Colegate B Palache L Hessel, Vaccine 2008 26 Suppl 4 23 26 10.1016/j.vaccine. 2008.07.067 19230154
44. Seasonal inactivated influenza virus vaccines. RB Couch, Vaccine 2008 26 Suppl 4 5 9 10.1016/j.vaccine.2008.05.076 18602728
45. Molecular and cellular signatures of human vaccine adjuvants. F Mosca E Tritto A Muzzi E Monaci F Bagnoli C Iavarone D O'Hagan R Rappuoli E De Gregorio, Proc Natl Acad Sci U S A 2008 105 30 10501 10506 10.1073/pnas.0804699105 18650390
46. A Simple, Rapid Technic of Preparing Water-in-Oil Emulsions of Penicillin, Drugs and Biologics. J Freund KJ Thomson, Science 1945 101 2627 468 469 10.1126/science.101.2627.468-a 17799002
47. Foot-and-Mouth Disease Virus Peptide Vaccines. DJ Rowlands, Foot-and-mouth Disease: Current Perspectives England: Horizon Bioscience, Sobrino F, Domingo E. Wymondham, 2004 335 354
48. Protection of cattle against foot-and-mouth disease by a synthetic peptide. R DiMarchi G Brooke C Gale V Cracknell T Doel N Mowat, Science 1986 232 4750 639 641 10.1126/science.3008333 3008333
49. The global impact of vaccination against hepatitis B: a historical overview. AR Zanetti P Van Damme D Shouval, Vaccine 2008 26 49 6266 6273 10.1016/j.vaccine.2008.09.056 18848855
50. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. MD Daniel F Kirchhoff SC Czajak PK Sehgal RC Desrosiers, Science 1992 258 5090 1938 1941 10.1126/science.1470917 1470917
51. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. PW Mason ME Piccone TS McKenna J Chinsangaram MJ Grubman, Virology 1997 227 1 96 102 10.1006/viro.1996.8309 9007062
52. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. R Andino D Silvera SD Suggett PL Achacoso CJ Miller D Baltimore MB Feinberg, Science 1994 265 5177 1448 1451 10.1126/science.8073288 8073288
53. Vaccines: engineering immune evasion. JR Mascola, Nature 2006 441 7090 161 10.1038/441161a 16688158
54. Development of a preventive vaccine for Ebola virus infection in primates. NJ Sullivan A Sanchez PE Rollin ZY Yang GJ Nabel, Nature 2000 408 6812 605 609 10.1038/35046108 11117750
55. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. ZY Yang WP Kong Y Huang A Roberts BR Murphy K Subbarao GJ Nabel, Nature 2004 428 6982 561 564 10.1038/nature02463 15024391
56. Influenza virus. FG Hayden P Palese, Clinical Virology New York: Churchill Livingstone, Richman DD, Whitley RJ, Hayden FG, 1997 911 942
57. Positive Darwinian evolution in human influenza A viruses. WM Fitch JM Leiter XQ Li P Palese, Proc Natl Acad Sci U S A 1991 88 10 4270 4274 10.1073/pnas.88.10.4270 1840695
58. Statistical analysis of nucleotide sequences of the hemagglutinin gene of human influenza A viruses. Y Ina T Gojobori, Proc Natl Acad Sci U S A 1994 91 18 8388 8392 10.1073/pnas.91.18.8388 8078892
59. Positive selection on the H3 hemagglutinin gene of human influenza virus A. RM Bush WM Fitch CA Bender NJ Cox, Mol Biol Evol 1999 16 11 1457 1465 10555276
60. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. K Koelle S Cobey B Grenfell M Pascual, Science 2006 314 5807 1898 1903 10.1126/science.1132745 17185596
61. Epidemiology. Influenza escapes immunity along neutral networks. E van Nimwegen, Science 2006 314 5807 1884 1886 10.1126/science.1137300 17185589
62. Evolutionary and immunological implications of contemporary HIV-1 variation. B Korber B Gaschen K Yusim R Thakallapally C Kesmir V Detours, Br Med Bull 2001 58 19 42 10.1093/bmb/58.1.19 11714622
63. Immunoinformatics comes of age. B Korber M LaBute K Yusim, PLoS Comput Biol 2006 2 6 71 10.1371/journal.pcbi.0020071 16846250
64. An introduction to epitope prediction methods and software. X Yang X Yu, Rev Med Virol 2009 19 2 77 96 10.1002/rmv.602 19101924
65. A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines. NC Toussaint P Dönnes O Kohlbacher, PLoS Comput Biol 2008 4 12 1000246 10.1371/journal.pcbi.1000246 19112482
66. Selectionism and neutralism in molecular evolution. M Nei, Mol Biol Evol 2005 22 12 2318 2342 10.1093/molbev/msi242 16120807
67. The Neutral Theory of Molecular Evolution. M Kimura, Cambridge, UK: Cambridge University Press 1983
68. Molecular signatures of natural selection. R Nielsen, Annu Rev Genet 2005 39 197 218 10.1146/annurev.genet.39.073003.112420 16285858
69. Statistical Method for Testing the Neutral Mutation Hypothesis by DNA Polymorphism. F Tajima, Genetics 1989 123 585 595 2513255
70. The coalescent. JFC Kingman, Stoch Proc Appl 1982 13 235 248 10.1016/0304-4149(82)90011-4
71. Genealogical trees, coalescent theory and the analysis of genetic polymorphisms. NA Rosenberg M Nordborg, Nat Rev Genet 2002 3 5 380 390 10.1038/nrg795 11988763
72. Heterosis or neutrality? GA Watterson, Genetics 1977 85 4 789 814 863245
73. The sampling theory of selectively neutral alleles. WJ Ewens, Theor Popul Biol 1972 3 1 87 112 10.1016/0040-5809(72)90035-4 4667078
74. Adaptive protein evolution at the Adh locus in Drosophila. JH McDonald M Kreitman, Nature 1991 351 6328 652 654 10.1038/351652a0 1904993
75. A codon-based model of nucleotide substitution for protein-coding DNA sequences. N Goldman Z Yang, Mol Biol Evol 1994 11 5 725 736 7968486
76. Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus. JB Plotkin J Dushoff, Proc Natl Acad Sci U S A 2003 100 12 7152 7157 10.1073/pnas.1132114100 12748378
77. Inferring Phylogenies. J Felsenstein, Sunderland, MA: Sinauer Associates 2003
78. Phylogenetics. C Semple M Steel, Oxford University Press 2003
79. Molecular Evolution and Phylogenetics. M Nei S Kumar, Oxford University Press 2000
80. Molecular Evolution: A Phylogenetic Approach. RDM Page EC Holmes, Oxford, UK: Blackwell Science 1998
81. A quantitative approach to a problem in classification. CD Michener RR Sokal, Evolution 1957 11 130 162 10.2307/2406046
82. The neighbor-joining method: a new method for reconstructing phylogenetic trees. N Saitou M Nei, Mol Biol Evol 1987 4 4 406 425 3447015
83. Construction of phylogenetic trees. WM Fitch E Margoliash, Science 1967 155 760 279 284 10.1126/science.155.3760.279 5334057
84. Long term trends in the evolution of H(3) HA1 human influenza type A. WM Fitch RM Bush CA Bender NJ Cox, Proc Natl Acad Sci U S A 1997 94 15 7712 7718 10.1073/pnas.94.15.7712 9223253
85. Quartet Puzzling: A Quartet Maximum-Likelihood Method for Reconstructing Tree Topologies. K Strimmer A von Haeseler, Mol Biol Evol 1996 13 964 969
86. MrBayes 3: Bayesian phylogenetic inference under mixed models. F Ronquist JP Huelsenbeck, Bioinformatics 2003 19 12 1572 1574 10.1093/bioinformatics/ btg180 12912839
87. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. SM Wolinsky BT Korber AU Neumann M Daniels KJ Kunstman AJ Whetsell MR Furtado Y Cao DD Ho JT Safrit, Science 1996 272 5261 537 542 10.1126/science.272.5261.537 8614801
88. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. A Meyerhans R Cheynier J Albert M Seth S Kwok J Sninsky L Morfeldt-Manson B Asjo S Wain-Hobson, Cell 1989 58 5 901 910 10.1016/0092-8674(89)90942-2 2550139
89. Multiply infected spleen cells in HIV patients. A Jung R Maier JP Vartanian G Bocharov V Jung U Fischer E Meese S Wain-Hobson A Meyerhans, Nature 2002 418 6894 144 10.1038/418144a 12110879
90. Network analysis of human and simian immunodeficiency virus sequence sets reveals massive recombination resulting in shorter pathways. S Wain-Hobson C Renoux-Elbe JP Vartanian A Meyerhans, J Gen Virol 2003 84 Pt 4 885 895 10.1099/vir.0.18894-0 12655089
91. Rapid viral quasispecies evolution: implications for vaccine and drug strategies. IS Novella E Domingo JJ Holland, Molecular Medicine Today 1995 1 248 253 10.1016/S1357-4310(95)91551-6 17607887
92. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. E Domingo L Menéndez-Arias ME Quĩones-Mateu A Holguín M Gutiérrez-Rivas MA Martínez J Quer IS Novella JJ Holland, Prog Drug Res 1997 48 99 128 9204684
93. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. PB Gilbert ML Ackers PW Berman DP Francis V Popovic DJ Hu WL Heyward F Sinangil BE Shepherd M Gurwith, J Infect Dis 2005 192 6 974 983 10.1086/432734 16107949
94. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. PB Gilbert ML Peterson D Follmann MG Hudgens DP Francis M Gurwith WL Heyward DV Jobes V Popovic SG Self,, et al. J Infect Dis 2005 191 5 666 677 10.1086/428405 15688279 (Pubitemid 40271053)
95. Retroviruses. JM Coffin SH Hughes HE Varmus, New York: Cold Spring Harbor Laboratory Press 1997
96. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. SP Buchbinder DV Mehrotra A Duerr DW Fitzgerald R Mogg D Li PB Gilbert JR Lama M Marmor C Del Rio,, et al. Lancet 2008 372 9653 1881 1893 10.1016/S0140-6736(08) 61591-3 19012954
97. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? RP Sekaly, J Exp Med 2008 205 1 7 12 10.1084/jem.20072681 18195078
98. Toward an AIDS vaccine. BD Walker DR Burton, Science 2008 320 5877 760 764 10.1126/science.1152622 18467582
99. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. S Rerks-Ngarm P Pitisuttithum S Nitayaphan J Kaewkungwal J Chiu R Paris N Premsri C Namwat M de Souza E Adams,, et al. N Engl J Med 2009 361 23 2209 2220 10.1056/NEJMoa0908492 19843557
100. HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine "success". J Cohen, Science 2009 326 5953 652 653 10.1126/science.326-652 19900904
101. HIV vaccine development by computer assisted design: the GAIA vaccine. ASD Groot L Marcon EA Bishop D Rivera M Kutzler DB Weiner W Martin, Vaccine 2005 23 17-18 2136 2148 10.1016/j.vaccine.2005.01.097 15755584
102. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. SA Thomson AB Jaramillo M Shoobridge KJ Dunstan B Everett C Ranasinghe SJ Kent K Gao J Medveckzy RA Ffrench,, et al. Vaccine 2005 23 38 4647 4657 10.1016/j.vaccine.2005.04.045 15964105
103. HIV-specific probabilistic models of protein evolution. DC Nickle L Heath MA Jensen PB Gilbert JI Mullins SLK Pond, PLoS One 2007 2 6 503 10.1371/journal.pone.0000503 17551583
104. Diversity considerations in HIV-1 vaccine selection. B Gaschen J Taylor K Yusim B Foley F Gao D Lang V Novitsky B Haynes BH Hahn T Bhattacharya,, et al. Science 2002 296 5577 2354 2360 10.1126/science.1070441 12089434
105. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. F Gao BT Korber E Weaver H-X Liao BH Hahn BF Haynes, Expert Rev Vaccines 2004 3 4 Suppl 161 S168 10.1586/14760584.3.4.S161 15285714
106. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. F Gao EA Weaver Z Lu Y Li H-X Liao B Ma SM Alam RM Scearce LL Sutherland J-S Yu,, et al. J Virol 2005 79 2 1154 1163 10.1128/JVI.79.2.1154-1163.2005 15613343
107. Molecular evolution. Active ancestral molecules. CB Stewart, Nature 1995 374 6517 12 13 10.1038/374012a0 7870163
108. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. NA Doria-Rose GH Learn AG Rodrigo DC Nickle F Li M Mahalanabis MT Hensel S McLaughlin PF Edmonson D Montefiori,, et al. J Virol 2005 79 17 11214 11224 10.1128/JVI.79.17.11214-11224.2005 16103173
109. Consensus and ancestral state HIV vaccines. DC Nickle MA Jensen GS Gottlieb D Shriner GH Learn AG Rodrigo JI Mullins, Science 2003 299 5612 1515 1518 author reply 1515-1518 10.1126/science.299.5612.1515c 12624248
110. Coping with viral diversity in HIV vaccine design. DC Nickle M Rolland MA Jensen SLK Pond W Deng M Seligman D Heckerman JI Mullins N Jojic, PLoS Comput Biol 2007 3 4 75 10.1371/journal.pcbi.0030075 17465674
111. Application of Phylogenetic Networks in E volutionary Studies. DH Huson D Bryant, Mol Biol Evol 2005 23 2 254 267 10.1093/molbev/msj030 16221896
112. Split decomposition: a new and useful approach to phylogenetic analysis of distance data. HJ Bandelt AW Dress, Mol Phylogenet Evol 1992 1 3 242 252 10.1016/1055-7903(92)90021-8 1342941
113. Multiply infected spleen cells in HIV patients. A Jung R Maier J-P Vartanian G Bocharov V Jung U Fischer E Meese S Wain-Hobson A Meyerhans, Nature 2002 418 6894 144 10.1038/418144a 12110879
114. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Zhuang AE Jetzt G Sun H Yu G Klarmann Y Ron BD Preston JP Dougherty, J Virol 2002 76 22 11273 11282 10.1128/JVI.76.22.11273-11282.2002 12388687
115. Recombination in HIV: an important viral evolutionary strategy. DS Burke, Emerg Infect Dis 1997 3 3 253 259 10.3201/eid0303.970301 9284369
116. Recombination in HIV and the evolution of drug resistance: for better or for worse? MT Bretscher CL Althaus V Müller S Bonhoeffer, Bioessays 2004 26 2 180 188 10.1002/bies.10386 14745836
117. Computing recombination networks from binary sequences. DH Huson TH Kloepper, Bioinformatics 2005 21 Suppl 2 i159 ii165 10.1093/bioinformatics/ bti1126 16204096
118. Method to Reconstruct the History of Sequences Subject to Recombination. JJ Hein, J Mol Evol 1993 20 402 411
119. Evidence of HIV-1 adaptation to HLA- restricted immune responses at a population level. CB Moore M John IR James FT Christiansen CS Witt SA Mallal, Science 2002 296 5572 1439 1443 10.1126/science.1069660 12029127
120. Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. G Ahlenstiel K Roomp M Däumer J Nattermann M Vogel JK Rockstroh N Beerenwinkel R Kaiser H-D Nischalke T Sauerbruch,, et al. Clin Vaccine Immunol 2007 14 10 1266 1273 10.1128/CVI.00169-07 17715334
121. Evolution and transmission of stable CTL escape mutations in HIV infection. PJ Goulder C Brander Y Tang C Tremblay RA Colbert MM Addo ES Rosenberg T Nguyen R Allen A Trocha,, et al. Nature 2001 412 6844 334 338 10.1038/35085576 11460164
122. Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. ZL Brumme CJ Brumme D Heckerman BT Korber M Daniels J Carlson C Kadie T Bhattacharya C Chui J Szinger,, et al. PLoS Pathog 2007 3 7 94 10.1371/journal.ppat.0030094 17616974
123. Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. JM Carlson ZL Brumme CM Rousseau CJ Brumme P Matthews C Kadie JI Mullins BD Walker PR Harrigan PJR Goulder,, et al. PLoS Comput Biol 2008 4 11 1000225 10.1371/journal.pcbi.1000225 19023406
124. Characterizing the Progression of Viral Mutations Over Time. AS Foulkes V DeGruttola, J Am Stat Assoc 2003 98 464 859 867 10.1198/016214503000000792 (Pubitemid 38213975)
125. Analysis of HIV-1 pol sequences using B ayesian Networks: implications for drug resistance. K Deforche T Silander R Camacho Z Grossman MA Soares KV Laethem R Kantor Y Moreau AM Vandamme BW non, Bioinformatics 2006 22 24 2975 2979 10.1093/bioinformatics/btl508 17021157
126. Learning multiple evolutionary pathways from cross-sectional data. N Beerenwinkel J Rahnenführer M Däumer D Hoffmann R Kaiser J Selbig T Lengauer, J Comput Biol 2005 12 6 584 598 10.1089/cmb.2005.12.584 16108705
127. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. N Beerenwinkel M Däumer T Sing J Rahnenführer T Lengauer J Selbig D Hoffmann R Kaiser, J Infect Dis 2005 191 11 1953 1960 10.1086/430005 15871130
128. A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. N Beerenwinkel M Drton, Biostatistics 2007 8 1 53 71 10.1093/biostatistics/kxj033 16569743
129. Conjunctive Bayesian networks. N Beerenwinkel N Eriksson B Sturmfels, Bernoulli 2007 13 4 893 909 10.3150/07-BEJ6133
130. Markov models for accumulating mutations. N Beerenwinkel S Sullivant, Biometrika 2009 96 3 645 661 10.1093/biomet/asp023
131. Quantifying cancer progression with conjunctive Bayesian networks. M Gerstung M Baudis H Moch N Beerenwinkel, Bioinformatics 2009 25 21 2809 2815 10.1093/bioinformatics/btp505 19692554
132. Computational methods for the design of effective therapies against drug resistant HIV strains. N Beerenwinkel T Sing T Lengauer J Rahnenführer K Roomp I Savenkov R Fischer D Hoffmann J Selbig K Korn,, et al. Bioinformatics 2005 21 21 3943 3950 10.1093/bioinformatics/bti654 16144807
133. Methods for optimizing antiviral combination therapies. N Beerenwinkel T Lengauer M Däumer R Kaiser H Walter K Korn D Hoffmann J Selbig, Bioinformatics 2003 19 Suppl 1 16 i25 10.1093/bioinformatics/btg1001 12855433
134. Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno-THEO on a Large Clinical Database. A Altmann M Däumer N Beerenwinkel Y Peres E Schülter J Büch S-Y Rhee A Sönnerborg WJ Fessel RW Shafer,, et al. J Infect Dis 2009 199 7 999 1006 10.1086/597305 19239365
135. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. A Altmann N Beerenwinkel T Sing I Savenkov M Däumer R Kaiser S-Y Rhee WJ Fessel RW Shafer T Lengauer, Antivir Ther 2007 12 2 169 178 17503659
136. The challenge of finding a cure for HIV infection. DD Richman DM Margolis M Delaney WC Greene D Hazuda RJ Pomerantz, Science 2009 323 5919 1304 1307 10.1126/science.1165706 19265012
137. An HIV vaccine - evolving concepts. MI Johnston AS Fauci, N Engl J Med 2007 356 20 2073 2081 10.1056/NEJMra066267 17507706
138. Immune control of HIV-1 after early treatment of acute infection. ES Rosenberg M Altfeld SH Poon MN Phillips BM Wilkes RL Eldridge GK Robbins RT D'Aquila PJ Goulder BD Walker, Nature 2000 407 6803 523 526 10.1038/35035103 11029005
139. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. ES Rosenberg JM Billingsley AM Caliendo SL Boswell PE Sax SA Kalams BD Walker, Science 1997 278 5342 1447 1450 10.1126/science.278.5342.1447 9367954
140. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. BT Korber NL Letvin BF Haynes, J Virol 2009 83 17 8300 8314 10.1128/JVI.00114-09 19439471
141. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. IK Srivastava JB Ulmer SW Barnett, Expert Rev Vaccines 2004 3 4 Suppl 33 52 10.1586/14760584.3.4.S33 15285704
142. HIV vaccine design and the neutralizing antibody problem. DR Burton RC Desrosiers RW Doms WC Koff PD Kwong JP Moore GJ Nabel J Sodroski IA Wilson RT Wyatt, Nat Immunol 2004 5 3 233 236 10.1038/ni0304-233 14985706
143. Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. E Yuste J Bixby J Lifson S Sato W Johnson R Desrosiers, J Virol 2008 82 24 12472 12486 10.1128/JVI.01382-08 18829751
144. Virus Dynamics. MA Nowak RM May, Mathematical Principles of Immunology and Virology New York: Oxford University Press Inc. 2000
145. Virus dynamics and drug therapy. S Bonhoeffer RM May GM Shaw MA Nowak, Proc Natl Acad Sci U S A 1997 94 13 6971 6976 10.1073/pnas.94.13.6971 9192676
146. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. AS Perelson AU Neumann M Markowitz JM Leonard DD Ho, Science 1996 271 5255 1582 1586 10.1126/science.271.5255.1582 8599114
147. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. H Mohri S Bonhoeffer S Monard AS Perelson DD Ho, Science 1998 279 5354 1223 1227 10.1126/science.279.5354.1223 9469816
148. Population dynamics of immune responses to persistent viruses. MA Nowak CR Bangham, Science 1996 272 5258 74 79 10.1126/science.272.5258.74 8600540
149. Viral dynamics in hepatitis B virus infection. MA Nowak S Bonhoeffer AM Hill R Boehme HC Thomas H McDade, Proc Natl Acad Sci U S A 1996 93 9 4398 4402 10.1073/pnas.93.9.4398 8633078
150. Viral dynamics in human immunodeficiency virus type 1 infection. X Wei SK Ghosh ME Taylor VA Johnson EA Emini P Deutsch JD Lifson S Bonhoeffer MA Nowak BH Hahn,, et al. Nature 1995 373 6510 117 122 10.1038/373117a0 7529365
151. Infectious diseases of humans. RM Anderson RM May, New York: Oxford University Press 1992
152. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. MA Nowak AL Lloyd GM Vasquez TA Wiltrout LM Wahl N Bischofberger J Williams A Kinter AS Fauci VM Hirsch,, et al. J Virol 1997 71 10 7518 7525 9311831
153. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. JD Lifson MA Nowak S Goldstein JL Rossio A Kinter G Vasquez TA Wiltrout C Brown D Schneider L Wahl,, et al. J Virol 1997 71 12 9508 9514 9371613
154. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. RT Schooley, AIDS 1995 9 Suppl 2 15 S19 8775802
155. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). B Autran RL Murphy D Costagliola R Tubiana B Clotet J Gatell S Staszewski N Wincker L Assoumou R El-Habib,, et al. AIDS 2008 22 11 1313 1322 10.1097/QAD. 0b013e3282fdce94 18580611
156. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. DL Sodora JS Allan C Apetrei JM Brenchley DC Douek JG Else JD Estes BH Hahn VM Hirsch A Kaur,, et al. Nat Med 2009 15 8 861 865 10.1038/nm.2013 19661993
157. Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise. U Fruth, Vaccine 2009 27 14 1989 1996 10.1016/j.vaccine.2008.12.029 19146900
158. Molecular basis for a lack of correlation between viral fitness and cell killing capacity. M Herrera J Garcia-Arriaza N Pariente C Escarmis E Domingo, PLoS Pathog 2007 3 4 53 10.1371/journal.ppat.0030053 17432933
159. Distribution of fitness and virulence effects caused by single-nucleotide substitutions in Tobacco Etch virus. P Carrasco F de la Iglesia SF Elena, J Virol 2007 81 23 12979 12984 10.1128/JVI.00524-07 17898073
160. Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. FJ Salguero MA Sanchez-Martin F Segundo Diaz-San A de Avila N Sevilla, Virology 2005 332 1 384 396 10.1016/j.virol.2004. 11.005 15661169
161. Fitness of RNA virus decreased by Muller's ratchet. L Chao, Nature 1990 348 6300 454 455 10.1038/348454a0 2247152
162. Genetic lesions associated with Muller's ratchet in an RNA virus. C Escarmis M Davila N Charpentier A Bracho A Moya E Domingo, J Mol Biol 1996 264 2 255 267 10.1006/jmbi.1996.0639 8951375
163. Virus attenuation by genome-scale changes in codon pair bias. JR Coleman D Papamichail S Skiena B Futcher E Wimmer S Mueller, Science 2008 320 5884 1784 1787 10.1126/science.1155761 18583614
164. Live attenuated influenza virus vaccines by computer-aided rational design. S Mueller JR Coleman D Papamichail CB Ward A Nimnual B Futcher S Skiena E Wimmer, Nat Biotechnol 28 7 723 726 10.1038/nbt.1636 20543832
165. Engineering attenuated virus vaccines by controlling replication fidelity. M Vignuzzi E Wendt R Andino, Nat Med 2008 14 2 154 161 10.1038/nm1726 18246077
166. Rationalizing the development of live attenuated virus vaccines. AS Lauring JO Jones R Andino, Nat Biotechnol 28 6 573 579 10.1038/nbt.1635 20531338
167. Models of parasite virulence. SA Frank, Quarterly Review of Biology 1996 71 1 37 78 10.1086/419267 8919665
168. Competition-colonization trade off in an RNA virus. S Ojosnegros N Beerenwinkel T Antal MA Nowak C Escarmis E Domingo, PNAS 2009
169. RNA virus quasispecies populations can suppress vastly superior mutant progeny. JC de la Torre JJ Holland, J Virol 1990 64 12 6278 6281 2173792
170. Density-dependent selection in vesicular stomatitis virus. IS Novella DD Reissig CO Wilke, J Virol 2004 78 11 5799 5804 10.1128/JVI.78.11.5799-5804.2004 15140977
171. Prisoner's dilemma in an RNA virus. PE Turner L Chao, Nature 1999 398 6726 441 443 10.1038/18913 10201376
172. Evolutionary feedback mediated through population density, illustrated with viruses in chemostats. JJ Bull J Millstein J Orcutt HA Wichman, Am Nat 2006 167 2 39 51 10.1086/499374 16670974
173. Interspecific competition and multispecies coexistence. D Tilman, Theoretical Ecology: Principles and Applications New York: Oxford University Press Inc, May RM, McLean, A.R., 2007
174. Computational Biology Group, Department of Biosystems Science and Engineering, ETH Zürcih http://www.bsse.ethz.ch/cbg/software/ct-cbn.
175. Centers for Disease Control and Prevention http://www.cdc.gov/vaccines/ vpd-vac/default.htm.